PXL/HO/Cir-019/2026-27                                                                                          Date: 25.05.2026

Hyderabad

Dear Members,

Subject: Operationalisation of the India–Oman FTA

The India–Oman Comprehensive Economic Partnership Agreement (CEPA), signed in December 2025, is tentatively scheduled for implementation from 01 June 2026. The Agreement is expected to create significant opportunities for the Indian pharmaceutical, AYUSH, and wellness sectors.

One of the immediate benefits under the CEPA framework would be the implementation of Zero Tariffs on Indian pharmaceutical products, including APIs and formulations, from the date of operationalization. The Department of Commerce will also facilitate consignments scheduled during the first half of June 2026 with the presence and support of senior officials. In this connection, member companies are requested to submit the details of consignments for Oman through the below link to enable Pharmexcil to coordinate and represent the same effectively:

GOOGLE FORM LINK

(Last date for submission: 28 May 2026)

As this is an important initiative being closely monitored by the Hon’ble Minister of Commerce & Industry, member companies exporting to Oman are requested to submit the information on an urgent basis.

Key Benefits for the Indian Pharma Sector under India–Oman CEPA

Ø  Fast-tracking of marketing authorizationsfor pharmaceutical products approved by stringent regulatory authorities such as USFDA, EMA, UKMHRA, etc.

Ø  Acceptance of GMP inspection documents, reducing approval timelines, compliance burden, and associated costs for Indian pharmaceutical exporters.

Ø  First-ever commitment by any country on Traditional Medicine across all modes, opening significant opportunities for India’s AYUSH and wellness sectors. The Agreement is expected to promote medical value travel and strengthen cooperation in traditional healthcare systems.

Ø  Enhanced market access and trade facilitation measures to improve export competitiveness for Indian pharma and healthcare products in Oman.

Ø  Zero tariffs on Indian pharmaceutical products, including APIs (Active Pharmaceutical Ingredients).

Click here for Pharma Annexure(Annexure 5A – Bilateral Cooperation on Pharmaceutical Products under India–Oman CEPA)

Click herefor Oman’s tariff commitments for Indian pharma products

Members are advised to explore business opportunities in formulations, APIs, AYUSH products, nutraceuticals, and wellness services under the CEPA framework.

Thanking you,

With Regards,

Raja Bhanu K

Director General